Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients?
Miyazawa
Keisuke
K
Nishimaki
Jiroh
J
Katagiri
Tomoko
T
Sashida
Goro
G
Shoji
Nahoko
N
Kawakubo
Ken
K
Suzuki
Akitaka
A
Shimamoto
Takashi
T
Gotoh
Akihiko
A
Kuriyama
Yuzuru
Y
Ito
Yoshikazu
Y
Tauchi
Tetsuzo
T
Kawanishi
Yoshikazu
Y
Kimura
Yukihiko
Y
Ohyashiki
Kazuma
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007564:Japan; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000139:chemically induced*
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate